Literature DB >> 3414801

Renal hemodynamics in response to a kinin analogue antagonist.

W H Beierwaltes1, O A Carretero, A G Scicli.   

Abstract

The influence of endogenous kinins on renal hemodynamics was studied using a kinin analogue antagonist ([DArg0-Hyp3-Thi5-DPhe7-Thi8]bradykinin) in eight sodium-restricted anesthetized dogs. Clearance periods were run during intrarenal infusion of vehicle or 50 micrograms/min of analogue during normal and reduced renal perfusion pressure within (95 mmHg) and below (65 mmHg) the range of renal autoregulation. During normal renal perfusion, the analogue did not affect arterial pressure, glomerular filtration rate (GFR), or sodium excretion but decreased renal blood flow (RBF) by 20% (6.41 +/- 0.35 vs. 5.61 +/- 0.38 ml.min-1.g kidney wt-1, P less than 0.05) due to increased renal vascular resistance (RVR, 0.44 +/- 0.03 vs. 0.54 +/- 0.04 U, P less than 0.01). The analogue increased renin secretion rate (RSR, 311 +/- 190 vs. 654 +/- 202 ng angiotensin I/min, P less than 0.001). With reduced renal perfusion (95 mmHg), RBF was unchanged, and sodium excretion and RVR decreased. Vehicle did not change GFR, but the analogue abolished autoregulation of GFR (-37%, P less than 0.02) and decreased filtration fraction (24 +/- 4 vs. 34 +/- 4%, P less than 0.05). Renal perfusion pressure of 65 mmHg decreased RBF, GFR, and sodium excretion similarly with vehicle or analogue. Converting-enzyme inhibition eliminated the changes in RVR. Thus kinin antagonism increased RSR and consequently RVR at normal renal perfusion. As renal perfusion pressure decreased, kinin antagonism diminished autoregulation of GFR but not of RBF. These results suggest that kinin antagonism may either modify the arteriolar resistance or alter the coefficient of filtration, resulting in decreased GFR at reduced renal perfusion pressure.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3414801     DOI: 10.1152/ajprenal.1988.255.3.F408

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

1.  The mechanism of bradykinin-induced endothelium-dependent contraction and relaxation in the porcine interlobar renal artery.

Authors:  E Ihara; K Hirano; D N Derkach; J Nishimura; H Nawata; H Kanaide
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

2.  Evidence for renal kinins as mediators of amino acid-induced hyperperfusion and hyperfiltration in the rat.

Authors:  A A Jaffa; C P Vio; R H Silva; R J Vavrek; J M Stewart; P F Rust; R K Mayfield
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

3.  Renal tubular responsiveness to atrial natriuretic peptide in sodium-retaining chronic caval dogs. A possible role for kinins and luminal actions of the peptide.

Authors:  L Legault; P Cernacek; M Levy; E Maher; D Farber
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

4.  Effects of Hoe 140, a bradykinin B2-receptor antagonist, on renal function in conscious normotensive rats.

Authors:  P Madeddu; V Anania; P P Parpaglia; M P Demontis; M V Varoni; G Pisanu; C Troffa; G Tonolo; N Glorioso
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

5.  Chronic kinin receptor blockade induces hypertension in deoxycorticosterone-treated rats.

Authors:  P Madeddu; V Anania; P P Parpaglia; M P Demontis; M V Varoni; M C Fattaccio; N Glorioso
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

Review 6.  The kallikrein-kinin system as a regulator of cardiovascular and renal function.

Authors:  Nour-Eddine Rhaleb; Xiao-Ping Yang; Oscar A Carretero
Journal:  Compr Physiol       Date:  2011-04       Impact factor: 9.090

7.  The effect of kinin and prostaglandin inhibitors on the renal response to angiotensin-converting enzyme inhibition: a micropuncture study in the dog.

Authors:  J Heller; H J Kramer; V Horácek
Journal:  Pflugers Arch       Date:  1994-06       Impact factor: 3.657

Review 8.  Role of Kinins in Hypertension and Heart Failure.

Authors:  Suhail Hamid; Imane A Rhaleb; Kamal M Kassem; Nour-Eddine Rhaleb
Journal:  Pharmaceuticals (Basel)       Date:  2020-10-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.